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Abstract 
Aim. Numerous genes are known to cause dilated cardiomyopathy (DCM). However, until 
now technological limitations have hindered elucidation of the contribution of all clinically 
relevant disease genes to DCM phenotypes in larger cohorts. We now utilized next-generation 
sequencing to overcome these limitations and screened all DCM disease genes in a large 
cohort. 
Methods and results. In this multi-centre, multi-national study, we have enrolled 639 patients 
with sporadic or familial DCM. To all samples, we applied a standardized protocol for ultra-
high coverage next-generation sequencing of 84 genes, leading to 99.1% coverage of the 
target region with at least 50-fold and a mean read depth of 2415. In this well characterized 
cohort, we find the highest number of known cardiomyopathy mutations in plakophilin-2, 
myosin-binding protein C-3, and desmoplakin. When we include yet unknown but predicted 
disease variants, we find titin, plakophilin-2, myosin-binding protein-C 3, desmoplakin, 
ryanodine receptor 2, desmocollin-2, desmoglein-2, and SCN5A variants among the most 
commonly mutated genes. The overlap between DCM, hypertrophic cardiomyopathy (HCM), 
and channelopathy causing mutations is considerably high. Of note, we find that >38% of 
patients have compound or combined mutations and 12.8% have three or even more 
mutations. When comparing patients recruited in the eight participating European countries 
we find remarkably little differences in mutation frequencies and affected genes. 
Conclusion. This is to our knowledge, the first study that comprehensively investigated the 
genetics of DCM in a large-scale cohort and across a broad gene panel of the known DCM 
genes. Our results underline the high analytical quality and feasibility of Next-Generation 
Sequencing in clinical genetic diagnostics and provide a sound database of the genetic causes 
of DCM. 
Translational Perspective 
We were able to show that targeted Next-Generation Sequencing is well suited to be applied 
in clinical routine diagnostics, substantiating the ongoing paradigm shift from low- to high-
throughput genomics in medicine. By means of our atlas of the genetics of human DCM, we 
aspire to soon be able to apply our findings to the individual patient with cardiomyopathy in 
daily clinical practice. 
 
 
 
Introduction 
Dilated cardiomyopathy (DCM) accounts for 30–40% of all heart failure cases in large clinical 
trials and is the leading cause of heart transplantation. There is ample data on the familial 
aggregation of DCM and in recent registers familial forms of DCM account for 30–50% of all 
DCM cases. With an autosomal-dominant inheritance being the predominant pattern of 
transmission, some familial cases also present by an autosomal recessive or X-linked recessive 
trait. Particularly in western countries, the small size of contemporary families may obscure 
the genetic nature of the disease and it is important to consider that also sporadic DCM cases 
can be due to genetic mutations.1 
 
Tremendous advances have been made in understanding the genetic basis of DCM. Linkage 
analyses in families and candidate gene sequencing as well as genome-wide association 
studies (GWAS) in large cohorts2 have contributed to the identification of risk variants and 
disease causing mutations in >30 disease genes, many of which encode for structural 
components of the heart muscle, such as the sarcomere or the cardiac z-disc. Recently, we 
and others have used Next-Generation Sequencing (NGS) approaches to dissect the genetic 
causes of DCM and established a comprehensive methodology for the clinical genetic testing 
of all currently known disease genes.3 However, the existing studies are either limited by the 
small number of investigated patients or the restriction to only a subset of disease genes, 
prohibiting a more detailed dissection of the role of DNA-alterations in DCM. 
 
We are here presenting the results of the gene sequencing study of the European 
INHERITANCE project including 639 patients with sporadic or proven familial DCM enrolled in 
eight different clinical centres (Denmark, Sweden, France, Italy, Germany, UK, Netherlands, 
and Spain). We aimed to systematically investigate not only the clinically relevant DCM genes 
but also genes causative for other inherited cardiomyopathies and to systematically 
benchmark the analytical performance of NGS as a novel technology being introduced into 
broad clinical application. 
 
Methods 
Patients and study design 
This multi-centre study was conducted in accordance with the principles of the Declaration of 
Helsinki. All participants from all centres have given written informed consent and the study 
was approved by the ethic committees of the participating study centres. 
 
Dilated cardiomyopathy was diagnosed according to the WHO/International Society and 
Federation of Cardiology Task Force clinical criteria,4 defined as a myocardial disorder 
characterized by the presence of left ventricular dilatation and systolic impairment, in the 
absence of abnormal loading conditions (e.g. hypertension, valve disease) or coronary artery 
disease (CAD) sufficient to cause global systolic dysfunction.5 Specific criteria were the 
presence of left ventricular dilatation (>117% of the predicted value corrected for age and 
body surface area using the Henry equation) and left ventricular systolic dysfunction (LVEF 
<45%) in the absence of abnormal loading conditions (e.g. hypertensive heart disease, 
primary valve disease) or CAD with stenosis >50% of at least one main vessel in coronary 
angiography. CAD was ruled out by coronary angiography in 53% of patients (n = 338). 
Patients having clinic suspicion or evidence for myocarditis [late-Gadolinium enhancement 
typical for myocarditis in cardiac MRI (69 patients (11%) of all patients undergone MRI), or 
evidence from myocardial biopsies (121 patients (19%) of all patients undergone biopsy)] or 
history of cardio-toxic therapies were excluded. Familial DCM was defined according to ESC 
definitions5 and evaluated according to the position statement of the European Society of 
Cardiology, Working Group on Myocardial and Pericardial Diseases.6 In detail, all familial DCM 
cases had at least one additional affected family member with DCM or one case of sudden 
cardiac death earlier 35 years of age in the pedigree. All criteria had to be met at an initial 
diagnosis of DCM in probands or relatives. Clinical data for association analysis were assessed 
during the index visit, where it was required that the patient was clinically stable for at least 
4 weeks. The enrolment was at the index visit of patients between 2009 and 2011, NGS was 
performed between March 2011 and August 2013 after DNA was extracted at the recruiting 
centre and shipped pseudonymized to the INHERITANCE sequencing core centre (Department 
of Cardiology, University of Heidelberg, Germany). 
 
Target enrichment, next-generation sequencing, and data analysis 
SureSelectXT Target Enrichment System (Agilent; Waldbronn, Germany) was used for 
capturing of the desired regions. Design of the capture baits was done using eArray (Agilent 
Technologies, Santa Clara, CA, USA). Raw data analysis was performed with an in-house 
pipeline based on variant calling of the Genome Analysis Toolkit (GATK). Annotation of the 
variants was mainly done using ANNOVAR. Genotype–phenotype association tests were done 
with the SAS software. For a detailed description of the data analysis, please refer to the 
Supplemental Material online. 
Variant classification 
In this study, we relied on distinct, well-defined categories for the classification of variants. 
Variants were classified as benign when present in ‘dbSNP137common’ 
(http://hgdownload.soe.ucsc.edu/goldenPath/hg19/database/snp137Common.sql) and 
flagged as validated-by-frequency, which means that those variants have been found with an 
allele-frequency of ≥1% in populations. For further determination of the likelihood to being 
disease relevant mutations, we defined distinct categories (see also Figure 1C): category Ia 
consists of coding human genome mutation database (HGMD) disease mutations (heart 
muscle diseases and channelopathies) and either are non-synonymous, frameshift insertions 
or deletions, splice or start/stop mutations. The same definition was applied for category Ib, 
where we additionally removed variants present in the 4300 individuals of the European-
Americans cohort of the NHLBI GO Exome Sequencing Project (ESP) database 
(http://evs.gs.washington.edu/EVS/). As category II, we defined all not common, truncating 
variants that are either frameshift insertions/deletions, splice, or start/stop variants. Finally, 
all not common non-synonymous variants with prediction ‘disease’ were classified as 
category III. The predictions were based on SNPs&GO (February/March 2013; 
http://snps.biofold.org/snps-and-go//snps-and-go.html).7  
 
Genotype–phenotype association analysis 
Association analyses were carried out using the SAS software version 9.2 (SAS Institute, Inc., 
Cary, NC, USA). Patients were characterized by gender, country, family history of DCM, LVEF, 
LVEDD, NYHA classification, age at diagnosis, heart transplantation, and implantation of ICD 
according to available information. Based on the above-described variant classification, the 
number of variants, the number of patients carrying at least one variant, the number of 
patients carrying at least two variants in a single investigated gene, and the number of 
patients carrying at least two variants in any investigated gene were calculated for each 
group. Probability values and effect sizes with 95% confidence intervals were estimated based 
on logistic and Poisson regression assuming a dominant penetrance model. To identify the 
most relevant DCM variants according to their function, a stepwise forward model selection 
was carried out. The list of explanatory variables included the variant carrier status in genes 
grouped by function (ion flux, nucleus, cell membrane, sarcomeric, cystoskeleton, and 
intercalated disc). Significant explanatory variables at the 5% level (score test) entered the 
models and they were not removed if they remained significant at the 10% level. Because of 
the exploratory nature of the genotype–phenotype association analysis, no correction for 
multiple testing has been applied. 
 
Results 
Ultra-high coverage next-generation sequencing enables comprehensive diagnostics of 
dilated cardiomyopathy 
For the purpose of this study, we designed and optimized a custom target-enrichment assay 
based on in-solution hybridization, targeting relevant genes involved in human DCM being 
summarized in Supplementary material online, Table S1. The custom target region 
encompasses all known coding exons of each gene. In total, we analysed 639 patients with 
known DCM diagnosed according to current ESC guidelines. Importantly, all 639 samples from 
the eight countries analysed in this study were processed according to the same standard 
operating procedures (SOPs) and quality control measures, allowing detailed inter-sample 
comparisons. Figure 1 details the origin of patients and the workflow applied. As shown in 
Table 1, the proportional number of patients with familial DCM was 49%. Left ventricular 
ejection fraction, indicating disease severity, was 31.2% (±12.1), while the NYHA functional 
class, being a measure of the individual clinical status, was mainly in I–III. Heart 
transplantation was performed in 113 patients and another 130 received ICD implantation. 
Gender distribution was as expected with more male patients being affected. For detailed 
patient characteristics, please refer to Table 1.  
 
As a pre-requisite for clinically applicable tests, we reached a very high 50-fold target 
coverage of 99.1% over all genes by iteratively improving the enrichment assay in a preceding 
establishment phase, being relevant to conclude positive as well as negative test results in 
individual patients. The mean coverage over all DCM genes was as high as 2526-fold (Figure 
2A). To determine the accuracy, specificity, and sensitivity of the proposed diagnostic tool, 
we followed-up 25 randomly selected amplicons containing at least one variant by Sanger 
sequencing. From 5909 readable bases in the Sanger sequencing, we observed 5879 true-
negative calls (TN) and 26 true-positive (TP) calls. Only three false-positive (FP) calls and one 
false-negative (FN) call were found, together resulting in a sensitivity [TP/(TP + FN)] of 96.3% 
and specificity [TN/(TN + FP)] of 100% and accuracy [(TP + TN)/(TP + FP + FN + TN)] of 99.9%. 
To further increase the depth of variants for benchmarking, we enriched and sequenced the 
well-genotyped HapMap sample NA12878 using the same methodology. When testing the 
standard GATK cut-off values, we find a sensitivity of 100% and an accuracy of 85.4%. Using 
our filter off-sets described in materials and methods, we achieved a much higher accuracy 
of 91.3% by maintaining a sensitivity of 99.0%. After manual inspection of the false-positives 
that could not be validated by Sanger, we postulated that at least some of these must be true 
variants. Hence, we exemplarily subcloned genomic DNA of patients with a variant call in the 
NGS data set and negative Sanger sequencing and sequenced individual clones. As shown in 
Supplementary material online, Figure S3, wild-type as well as mutant clones from one 
individual can be found, which is not obvious in the Sanger sequence, indicating that the 
actual accuracy of NGS is even higher than the estimated and that Sanger sequencing may 
miss at least some of the variants.  
 
Distribution of mutations in dilated cardiomyopathy patients 
In total, we identified 8269 unique genetic variants, adding up to 359 669 variants in the 639 
patients across the investigated target region. On average, each patient carries 563 variants 
in this region. To gain information on the relevance of each variant, we performed a stepped 
filtering approach, first by eliminating known common variants. We thereafter annotated the 
remaining variants using ANNOVAR, snpEff, Genometrax (Biobase), and SNPs&GO. 
 
We then applied the classification presented in Figure 1C. A known cardiomyopathy mutation 
(category Ia; reported in HGMD as cardiomyopathy or channelopathy variant) was found in 
305 patients (48% of all patients). When we additionally excluded variants observed in a large 
non-DCM control cohort (ESP whole exome sequencing project8) (=category Ib), we still find 
in 294 patients (46%) a known mutation previously reported as disease causing. Figure 2B 
gives an overview over the distribution of mutations across the screened DCM genes. When 
considering only DCM-causing mutations by excluding mutations of other cardiomyopathies, 
a known mutation is found in 101 patients (16% of all patients). 
 
Since many cardiomyopathy cases will be caused by rare or private mutations, which are not 
yet annotated in databases such as HGMD, we next searched in all patients for ‘likely’ disease 
mutations (category II). The ‘likely’ mutations include frameshift insertions/deletions, stop-
gain/-loss variants, and splice-site mutations within the target genes. In addition to the 
category Ia variants, our analysis yielded insertions with resulting frameshifts in three 
different genes across 13 patients and frameshift deletions in 10 DCM genes covering a total 
of 37 patients. We also identified 11 individual splicing variants in 8 DCM genes in a total of 
37 patients and 60 stop-gain/-loss variants in 17 genes in another 67 patients. Altogether, we 
find 117 previously not annotated highly ‘likely’ pathogenic variants in 26 genes for 147 
patients (23%). 
 
To search for ‘potential’ disease mutations (category III), we selected all non-common, non-
synonymous variants, and applied bioinformatics methods to predict a detrimental effect of 
each variant on the protein function. By using SNPs&GO, we classified as many as 939 variants 
as neutral and 141 unique variants as potentially disease causing. These 141 variants were 
detected in 221 patients and are rare judged by their frequency. Figures 3 and 4 exemplify 
the distribution of variants for representative disease genes (Nexilin, Titin, Lamin A/C). See 
also Supplementary material online, Figure S1 for the whole list of genes. To investigate 
whether the variants from category II–III indeed represent rare mutations, we calculated the 
percentage of Singletons, which means variants found uniquely in only one patient. Here, the 
rate was 21.8% in the categories II–III, compared with 1.6% in the removed variants, 
underlining the stringency of the classification approach.  
 
Looking at the total number of variants within the DCM genes, the majority of variants (13%) 
can be found in the titin gene (TTN) (Figure 5A). This is not surprising since TTN is the largest 
human gene and accounts for >20% of the total target region. When normalizing, the number 
of variants to the size of each gene (Figure 5B), a rather even distribution can be found, 
disproving the existence of instability hotspots in DCM genes. A detailed view on the 
distribution of all likely and potentially pathogenic variants is given in Figure 5C showing the 
number of splice, frameshift, stop, non-synonymous, and predicted disease causing 
(SNPs&GO) non-synonymous variants.  
 
Distribution of the functional effects of dilated cardiomyopathy mutations 
Numerous studies suggest different phenotypic manifestations or severities depending on the 
gene affected, type and number of mutations. Hence, we tested if DCM patients in our cohort 
might carry multiple disease mutations, e.g. compound mutations (category Ib–III). Strikingly, 
such compound heterozygous states were found in 49 (7%) patients and combined 
heterozygous mutations were found in 243 patients (38%). Remarkably, we detected in 82 
patients (12.8%) at least 3 mutations (Table 2). Considering only the very stringent category 
Ib variants of annotated disease mutations after exclusion of variants detected in additional 
control cohorts, still 82 patients (12.8%) carry at least 2 known disease mutations. As 
expected, using logistic regression, we find a significant association of patients having a 
disease mutation and familial DCM (P = 0.03, category Ib–III) (Table 3). To test if those results 
are driven by an effect of the large ttn gene, we repeated the analysis after exclusion of any 
ttn variant and still find 79 patients (12.4%) with at least two category Ib variants 
(Supplementary material online, Table S5).  
 
When looking more closely at the variants annotated using the HGMD database (CatIb), a 
large portion of disease causing mutations are known to cause arrhythmogenic right 
ventricular cardiomyopathy (ARVC) (31%), HCM (16%), or channelopathies (6%) (Figure 6A), 
indicating a marked overlap not only related to disease genes, but also to specific mutations 
in cardiomyopathies. Hence, based on current literature, all genes investigated in this study 
were classified according to the different cell components or functions they contribute to 
(Supplementary material online, Table S1).9 Next, we summed up the number of patients 
carrying a category Ib mutation in the different groups. Figure 6B details the groups and the 
identified number of patients. Based on this classification, the sarcomere group shows the 
highest number of patients having a mutation (14%), followed by ion flux (13%), z-
disc/cytoskeleton (12%), and intercalated disc (11%).  
 
We next asked whether we might identify specific genotype–phenotype associations in this 
large cohort. This would have direct clinical implications, since a genotype-guided risk 
assessment could improve patient selection for intensified monitoring or directed therapies. 
First, we investigated the gene groups introduced above and the available phenotypes. In an 
exploratory association analysis by using a stepwise forward selection, we could identify a 
logistic regression model for the group ‘nucleus’ being a significant predictor for ICD-carrier 
status in DCM (unadjusted P = 0.02). The odds ratio (OR) for patients carrying such variants 
was 2.44 [95% confidence interval (95% CI): 1.13–5.28]. This association was mainly driven by 
the nuclear gene RBM20, having an OR of 5.65 (1.89–16.86; P = 0.002). For the age at 
diagnosis, which might be relevant for establishing genetic testing in relatives, we find a 
significant association between MYH6 and ADRB3 mutations (Tables 4 and 5). Other clinically 
relevant associations were found for SMYD1, which we here suggest as novel disease gene 
for DCM, as well as for alpha-crystalin B (CRYAB) mutations, both were associated with LVEF. 
Alterations in left-ventricular diameter (LVEDD) could be seen in association with TBX20 (OR: 
0.45, 0.22–0.94; P = 0.03). Since a significant number of patients also received heart 
transplantation (HTX) due to end-stage heart failure (20% of the cohort), we investigated 
associations with HTX. Here, we found a significant association with MYPN having an OR of 
4.23 (1.04–17.18).  
 Differences of dilated cardiomyopathy mutations across Europe 
This study includes a total of 639 patients from eight countries, enabling us to investigate the 
geographical distribution of cardiomyopathy relevant variants. When considering genetic 
variants from category Ib–III (Supplementary material online, Table S6), we observe small yet 
statistically significant differences between countries regarding the rate of mutations 
(variants per patient), with Germany showing the lowest rate of 0.98 and Great Britain 
showing the highest rate of 1.51 (global P = 0.04, Poisson regression). The rate of mutation 
positive patients for single genes and across countries is depicted in Figure 7. For example, 
the rate of patients carrying a TTN variant ranged from 0.56 in Dutch patients to 0.20 in 
German patients (global P < 0.001, logistic regression). However, mutation frequencies of 
DCM genes are clearly more homogeneous than previously reported in smaller studies, 
suggesting that genetic testing for DCM can be applied in a uniform setting across Europe.  
 
Discussion 
To our knowledge, this is the most comprehensive study on the contribution of DCM-causing 
genes to date. The data reported shed light on the distribution of genes, the number of 
mutations and mutational burden of patients with DCM. 
 
Next-generation sequencing technologies (NGS) have emerged as a fast alternative to Sanger-
sequencing, providing the analytical characteristics for the comprehensive exploration of 
genetic mechanisms.10 However, NGS retains some weaknesses, such as the incomplete 
representation and coverage of exons, bearing the risk of limited sensitivity and detection 
failure of clinically relevant mutations. The use of target enrichment followed by NGS, for 
high-throughput genetic testing of disease genes for DCM, HCM and other cardiomyopathies 
has now become feasible and technically validated as shown by the nearly complete coverage 
and high accuracy of the approach described here. 
 
To reduce the number of likely and potentially pathogenic variants, bioinformatics analyses 
must include a filter step, e.g. excluding common variants present in databases like dbSNP. 
However, it is known that dbSNP is ‘contaminated’ with a small but yet substantial number of 
pathogenic alleles.11 On the other hand, disease mutation databases contain potentially 
benign variants, previously classified as disease causing. Therefore, to substantiate the 
disease causing nature of a variant, further investigations must include a screening of well-
phenotyped control cohorts from diverse populations and a detailed follow-up on the clinical 
circumstances in each patient and family, for example, by co-segregation analyses. But since 
families are often small and many patients are classified as sporadic, the ultimate solution of 
this intricate problem seems illusive. Mestroni and Taylor12 recently reviewed how the 
progress in genetic research already changed the view on the genetic basis of DCM. It is hence 
obvious that bioinformatics strategies must grow together with the enormous amount of data 
from adequately sized and high-quality NGS studies. With regard to a functional prediction, 
Thusberg et al.13 observed significant differences between algorithms, but found that 
algorithms such as the here applied SNPs&GO perform already surprisingly well. However, at 
least by now, proving new variants or genes as disease causing requires further efforts to 
validate them through functional and familial studies and large-scale population-based 
control cohorts sequenced by NGS. 
 
Previous publications have given rise to the notion that disease-causing gene mutations may 
underlie geographical disparities.14 In our study, we enrolled patients from eight countries to 
create a European map of cardiomyopathy relevant variants and find only modest differences 
across the countries. We observed the lowest number of variants in the German cohort when 
compared with the other countries. This effect may be due to a higher number of patients in 
Germany bearing sporadic forms of DCM. However, differences caught our attention for 
Sweden, where we detected the most category Ib–III variants in DSP and MYBPC3 compared 
with the other countries, as well as for the Netherlands, where we observed the highest 
number in TTN variants. With respect to PLN, we only uncovered one single mutation in our 
study population, suggesting that the previously mentioned mutation frequencies might 
express a very local phenomenon rather than a common cause of DCM. The overall 
distribution of mutations in DCM disease genes all over the participating countries appeared 
to be more homogeneous than expected. 
 
In clinical routine, only detailed workup of cases and their families allows to uncover familial 
aggregation.15 Often this is impeded by small family structures, unavailable family members 
or incomplete penetrance, which classifies many cases as sporadic or idiopathic. However, 
this does not exclude a genetic cause of DCM in this individual patient. By introducing familial 
and sporadic DCM cases in our study, we were able to compare both groups in a 
comprehensive and well-controlled manner. By doing so, we observed significantly higher 
mutation rates in familial cases than in the sporadic ones (OR: 1.52). However, as shown, we 
find also in many cases of idiopathic DCM a known and well-characterized disease mutation. 
Hence, the current work underlines that even if a definite familial DCM may not be proven, a 
genetic aetiology cannot be ruled out. The decision to genetically test sporadic cases should 
be, however, taken carefully to avoid unnecessary costs and inconclusive results. By limiting 
testing to familial DCM and risk groups of idiopathic DCM, e.g. with documented arrhythmias, 
would be an apparent conclusion. 
 
Genotype–phenotype correlations will be of increasing importance to predict the clinical 
manifestations of genetically diagnosed patients. However, there are few existing studies on 
genotype–phenotype correlations in selected cohorts. Convincing data exist for the clinical 
impact of LMNA. Here, several studies have repeatedly shown a poor prognosis for LMNA 
mutation carriers due to the occurrence of ventricular arrhythmias and sudden cardiac 
death.16 Similarly, it was shown that RBM20 mutation carriers with DCM present with a fast 
progression of heart failure and high risk for arrhythmias.17 In our study, the often-maligned 
stop or frameshift mutations in LMNA ranked within the top three genes of our tested gene 
panel and we find LMNA to having together with RBM20 the most category Ib–III mutations 
for genes with a comparable size. While we observed a significant association of ICD-carriers 
with the functional gene group ‘nucleus’ to which LMNA belongs, a statistically significant 
effect could only be seen for RBM20, where we find an association with the ICD-carrier status. 
It should be kept in mind that present results rely on a small number of observations for some 
strata and that probability values are not corrected for multiplicity. When using an exact test, 
the probability value MYPN and HTX (P = 0.04) decreases to P = 0.0051, while the probability 
value for CRYAB (P = 0.04) decreases to P = 0.02 and RBM20 (P = 0.002) remains unchanged. 
While for RBM20 our results may be seen as validation of previous findings and hence 
underline the importance for testing this gene now routinely, the newly found associations 
require additional replication in independent cohorts of DCM patients. 
 
Remarkably, we find in our DCM cohort a high percentage of mutations previously described 
for HCM, ARVC, or channelopathies, which questions the hypothesis of the allelic nature of 
cardiomyopathies. For instance, we found plakophilin-2 to be the most frequently affected 
gene when considering only known pathogenic mutations. Plakophilin-2 mutations represent 
a frequent cause of ARVC, which is characterized by the degeneration of cardiomyocytes and 
resulting arrhythmias.18 A similar finding was recently provided by Pugh et al.,19 underlining 
that our findings are not spurious. While they hypothesized that misdiagnosis in their broad 
referral population of an ordering provider could be one potential explanation, we nearly can 
exclude this due to the controlled setting of our study. To avoid phenotypic misclassification, 
we relied on experienced clinicians for recruiting to our best knowledge only DCM patients 
and performed additional phenotyping by coronary angiography, cMRI, or myocardial biopsy 
where appropriate. We rather hypothesize a pathophysiological link between conductance 
defects and resulting cardiac mechanical disparities. However, even then a certain overlap of 
phenotypes will explain at least a part of these findings. 
 
We were to our knowledge first to introduce genetic testing of cardiomyopathy patients for 
the large TTN gene using NGS.3 In accordance with recent findings by Herman et al.20 reporting 
TTN truncating mutations to be the cause of DCM in ∼25% of familial and in 18% of sporadic 
cases, we were able to identify such mutations in 19% of familial and 11% of sporadic cases. 
Interestingly, 44% of all patients with a truncating TTN variant also had additional known 
disease-causing variants in at least one other gene, suggesting that in these cases, the TTN 
variant may not be the sole cause of DCM, underlining the importance to investigate a broad 
gene panel rather than selected genes.19 In this regard, this study sheds for the first time light 
on the role of TTN and other mutations to DCM in a considerable high number of patients. 
This is also underlined by the high clinical sensitivity of our approach of 46% (considering only 
known mutations, cat Ib) up to 73.2% (considering cat Ib–III), which is already in the range of 
the sensitivity reported for HCM.21 This is in contrast to previous studies that reported lower 
sensitivity values, maybe due to more inhomogeneous cohorts or the use of NGS in subgroups 
of patients.19 This maybe also the reason why MYBPC3 mutations, which we surprisingly find 
very frequently, could not be associated with DCM in some previous studies and hence was 
long debated if it contributes to DCM at all. For the group of patients without Ib–III variants 
(26.7%), family-based whole exome sequencing or alternative approaches should be applied 
to identify possible genetic defects in so far unknown disease genes, with BAG3 being one 
recent example.22,23 
 
Even if genetic investigations do not resolve a familial disease, other mechanisms such as 
epigenetic modifications (microRNAs, Histon-modifications, DNA methylation) should be 
taken into account.10,24 Only very recently, first studies underlined the role of DNA 
methylation on heart failure and DCM.25,26 While the studies did not provide evidence for the 
causality or inheritance of the observed changes, it will be interesting to investigate the 
shown proof-of-principle in pedigrees with DCM. Furthermore, the increasing numbers of 
genetic susceptibility loci harbouring common polymorphisms add to the concept that DCM 
is a complex disorder, with rare and common genetic variants and environmental factors 
driving disease onset and outcome. 
 
With improved accuracy, efficiency, and decreasing cost, NGS is becoming the sole standard 
for gene sequencing. It must be noted that high analytical standards must be the basis for 
introducing such methodology for the diagnostics of DCM. We were able to show high-
analytical fidelity and consistency in a large patient cohort, demonstrating that targeted NGS 
is already well suited to be applied in clinical routine diagnostics, substantiating the ongoing 
paradigm shift from low- to high-throughput genomics in medicine. However, many third 
party providers do not publish quality indices that should be pre-requisite for introducing 
their technologies into the clinics. Our study hopefully stimulates not only the single physician 
to demand for transparency in regard to quality but also helps to impact on future 
recommendations for the next-generation of genetic testing. By means of our atlas of the 
genetics of human DCM, we aspire cardiologist and human geneticists to soon be able to 
apply our findings to the individual patient with cardiomyopathy in daily clinical practice. 
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Table 1: Patient characteristics. 
Characteristics DCM patients (n=639) 
Gender (%) 
Woman                                                                       
Man 
 
212(34) 
405(66) 
Family history familial DCM (%) 
Sporadic 
Familial 
 
 
271 (51) 
265(49) 
LVEF (%) 
LVEDD (mm) 
 
31.2 ± 12.1 
64.4 ± 11.2 
  
NYHA functional class (%)  
 I 145(28) 
 II 164(32) 
 III 165(32) 
 IV 
 
39(8) 
Received heart transplantation (%) 
No 
Yes 
 
 
                          465(80) 
                          113(20) 
 
Received ICD implantation (%) 
No 
Yes 
 
344(73) 
130(27) 
 
Table 2: Multiple mutations affecting single patients. 
Number of 
mutations 
HGMD1 variants  
Patients, (%) 
Category Ib-III2 variants 
Patients, (%) 
0 345 (54.0%) 171 (26.7%) 
≥1 294 (46.0%) 468 (73.2%) 
≥2 81 (12.7%) 243 (38%) 
≥3 14 (2.2%) 82 (12.8%) 
≥4 2 (0.3%) 16 (2.5%) 
1 = either category Ib or category II or category III. 
 
 
Table 3: Association of familial and sporadic DCM with number of mutation positive results. 
 
 
No. of 
patients 
No. of patients having 
category Ib-III1 variant 
p-value from  
logistic regression 
OR (95% CI) 
Sporadic DCM 271 186 0.03 Reference 
Familial DCM 265 203  1.52 ( 1.04- 2.23) 
1 = either category Ib or category II or category III. OR=Odds Ratio; CI=Confidence Interval 
Table 4: Association between genotypes and DCM. 
Gene Phenotype No. of patients Patients with 
category Ib-III1 
variants 
p-value from 
logistic regression 
OR (95% CI) 
CRYAB LVEF 582 2 0.04 0.05 ( 0.00- 0.81) 
      
MYPN received HTX     
 - no 465 4  Reference 
 - yes 113 4 0.04 4.23 ( 1.04-17.18) 
      
RBM20 received ICD     
 - no 344 5 0.002 Reference 
 - yes 130 10  5.65 ( 1.89-16.86) 
SMYD1 LVEF 582 2 0.03 4.42 ( 1.14- 17.10) 
TBX20 LVEDD 538 7 0.03 0.45 ( 0.22- 0.94) 
MYH6 Age at diagnosis 439 8 0.03 0.63 ( 0.41- 0.96) 
ADRB3   2 0.04 0.36 ( 0.14- 0.94) 
      
Only significant associations are shown. 1 = either category Ib or category II or category III. OR=Odds Ratio; CI=Confidence 
Interval. 
Table 5: Mutation counts by country. 
 
No. of 
patients  
No. of category Ib-
III1 variants 
p-value 
Poisson regression 
Effect (CI) 
Country     
Denmark 100 130 0.04 Reference 
England 70 106  1.16 (0.90- 1.51) 
France 92 111  0.93 (0.72- 1.20) 
Germany 98 93  0.73 (0.56- 0.95) 
Italy 78 97  0.96 (0.74- 1.24) 
Netherlands 70 99  1.09 (0.84- 1.41) 
Spain 82 107  1.00 (0.78- 1.30) 
Sweden 49 71  1.11 (0.83- 1.49) 
1 = either category Ib or category II or category III. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure Legends 
Figure 1 
Study design. (A) The map is showing the participating European countries and the number 
of patients included (absolute and in brackets relative). Map (EU27-
European_Union_map.svg) by Kolja21, used under CC BY. (B) Applied workflow, consisting of 
target-enrichment of cardiomyopathy related genes, next-generation sequencing and data 
analysis. (C) Overview of variant classification. Total number of patients in the whole cohort 
is given in brackets. 
 
 
Figure 2 
Sequence coverage and variant distribution per Gene. (A) Graph representing the sequence 
coverage of dilated cardiomyopathy genes. Vertical axis is showing the target coverage for 
every gene, colour codes give the read depth of coverage. The horizontal axis is giving the 
mean coverage in reads per gene (pale green line). Over all dilated cardiomyopathy genes a 
mean coverage of 2526 could be found. (B) Bar graph demonstrating the distribution of 
identified known disease causing mutations (category Ia) in the whole patient cohort over all 
tested dilated cardiomyopathy genes. Colour code is giving information on the different CMP 
subtypes as annotated in HGMD. Dilated cardiomyopathy mutations are painted in petrol, 
hypertrophic cardiomyopathy, ARVC, LongQT, and Brudgada mutations are coloured in blue, 
ranging from dark to pale. 
 
 
Figure 3 
Variant distribution in NEXN. The high coverage of each gene, exemplified for the nexilin gene, 
enables a reliable read mapping, variant calling and subsequent filtering of genetic variants. 
The black boxes below the coverage plot are representing the targeted region of the NEXN 
gene. Sequence alignments show the variants and their chromosomal location. The scheme 
at the bottom of the figure gives an overview on the variant classification. In total, seven 
different non-synonymous variants and one stop mutation in two patients and one non-
frameshift variant in one patient were found in NEXN. Numbers in brackets are the total sum 
of variants found in the cohort. Predicted benign = green; deleterious = red. 
 
Figure 4 
Variant classification in TTN and LMNA. Diagrams are showing the number of individual 
variants of different types for (A) titin and (B) lamin. Numbers in brackets are the total sum 
of variants found in the cohort. HGMD disease variants (category Ia) were annotated using 
the Biobase Human Genome Mutation Database, regardless of their appearance in 
dbSNP137common. All subcategories (non-synonymous, frameshift, stop/start, predicted 
disease, predicted benign, splicing, synonymous) were annotated after removing those 
common variants. For prediction of non-synonymous variants, SNPs&Go was used. Colours of 
the boxes indicate a potential benign (green) or deleterious (red) effect. Variant 
categorization is indicated below the deleterious variant types. Sketch below the diagram is 
showing the target region of the gene (black) and the distribution of common (green) and 
known and likely/potential pathogenic variants (red). 
 
Figure 5 
Variant distribution in dilated cardiomyopathy genes. Pie charts representing the total 
number of variants per dilated cardiomyopathy genes (A) and after normalization to the gene 
size (B). (C) Blue bar graphs are showing the total number of variants over all patients by 
predicted effect type for each gene (splice, frameshift, stop, non-synonymous, and predicted 
disease). Curly bracket is grouping the likely truncating variants (category II) and indicates the 
potential disease causing variants (category III). 
 
Figure 6 
Variant distribution and classification by cell components. (A) Variants were annotated using 
HGMD and filtered by Exome Sequencing Project variants (category Ib). Within all annotated 
mutations, we find the highest number described to cause dilated cardiomyopathy (35%), 
ARVC (31%) and hypertrophic cardiomyopathy (16%). Also, a substantial number is found for 
Long QT and Brugada syndrome (left pie chart). The right pie chart is giving percentages of 
affected patients in relation to dilated cardiomyopathy-cohort size (n = 639). B) Genes were 
grouped based on their contribution to different cellular compartments or functions in six 
groups (ion flux, nucleus, cell membrane, sarcomere, z-disc/cytoskeleton or intercalated disc). 
Given are the number (percentage) of patients carrying a category Ib disease mutation. 
Patients having a variant in more than one group were counted multiple times. 
 
Figure 7 
Country-specific rates of mutation positive patients by dilated cardiomyopathy genes. The 
rates of patients carrying at least one category Ib–III variant per gene are represented by 
coloured dots, 95% Clopper–Pearson confidence interval are indicated by coloured lines. 
Countries without mutations in a certain gene are not plotted. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
  
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
